You are here

  • Home
  • Archive
  • Volume 92, Issue 3
  • Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

Article info

Article menu

Download PDFPDF

Original Article
Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

Authors

  1. Dr S Michels, Department of Ophthalmology, University Hospital Zürich, Frauenklinikstrasse 24, 8091 Zürich, Switzerland; stephan.michels{at}usz.ch
View Full Text

Citation

Weigert G, Michels S, Sacu S, et al
Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
British Journal of Ophthalmology 2008;92:356-360.

Publication history

  • Accepted September 11, 2007
  • First published February 26, 2008.
Online issue publication 
March 22, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2008 BMJ Publishing Group Ltd